Janssen China
Johnson & Johnson operates across pharmaceuticals, medical devices and consumer health with activities in clinical programs, product R&D, manufacturing and public health initiatives. The provided content highlights national neonatal and maternal health training programs, vaccine research (including a COVID-19 vaccine program), collaborations on digital health and wearable-based AFib detection, adoption of AI and cloud technologies to accelerate medical innovation, large-scale contact lens manufacturing, development and regulatory submission of medical-device and biomaterial products, and sustainability and community health projects in China.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Mass-produced contact lenses
High-volume manufactured ophthalmic soft contact lenses for consumer and clinical use.
Hemostatic biomaterial product (aggregate particle formulation)
A hemostatic biomaterial product based on aggregated particle technology that obtained regulatory approval via an accelerated review pathway in China.
COVID-19 vaccine development program (candidate vaccine)
Research and development program to create a preventive vaccine against SARS-CoV-2, including preclinical work and progression toward clinical evaluation.
Mass-produced contact lenses
High-volume manufactured ophthalmic soft contact lenses for consumer and clinical use.
Hemostatic biomaterial product (aggregate particle formulation)
A hemostatic biomaterial product based on aggregated particle technology that obtained regulatory approval via an accelerated review pathway in China.
COVID-19 vaccine development program (candidate vaccine)
Research and development program to create a preventive vaccine against SARS-CoV-2, including preclinical work and progression toward clinical evaluation.
Services
Nationwide in-person training delivered to healthcare providers and birth attendants to teach neonatal resuscitation techniques and reduce newborn mortality.
Workshops using additive manufacturing to design and produce assistive aids for children with disabilities.
Nationwide in-person training delivered to healthcare providers and birth attendants to teach neonatal resuscitation techniques and reduce newborn mortality.
Workshops using additive manufacturing to design and produce assistive aids for children with disabilities.
Expertise Areas
- Maternal and neonatal health programs
- Vaccine research and clinical development
- Digital health and wearable sensor evaluation
- AI-driven drug discovery and analytics
Key Technologies
- Artificial intelligence and machine learning
- Big data and cloud-based analytics
- Wearable sensor integration for health monitoring
- Vaccine platform technologies
News & Updates
Article describing a decade-long neonatal resuscitation training program that reached thousands across China and contributed to newborn survival.
Article about infant massage programs and their role in supporting brain development and rehabilitation for preterm and at-risk infants.
Overview of efforts to develop a preventive vaccine against the novel coronavirus (SARS-CoV-2) and related research activities.
Announcement of a collaboration to evaluate wearable devices for early identification of atrial fibrillation to improve screening and prevention.
Report of regulatory approval for a hemostatic aggregate particle product via an accelerated innovation channel in China.
Publication of the company's 2020 health and sustainability report summarizing public health commitments and sustainability activities.
Article describing a decade-long neonatal resuscitation training program that reached thousands across China and contributed to newborn survival.
Article about infant massage programs and their role in supporting brain development and rehabilitation for preterm and at-risk infants.
Overview of efforts to develop a preventive vaccine against the novel coronavirus (SARS-CoV-2) and related research activities.
Announcement of a collaboration to evaluate wearable devices for early identification of atrial fibrillation to improve screening and prevention.
Report of regulatory approval for a hemostatic aggregate particle product via an accelerated innovation channel in China.
Publication of the company's 2020 health and sustainability report summarizing public health commitments and sustainability activities.